You have free access to this content

Cancer

Cover image for Vol. 118 Issue 14

15 July 2012

Volume 118, Issue 14

Pages 3447–3665

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
    2. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
      Predicting toxicity from radiation therapy—It's genetic, right? (pages 3450–3454)

      Chris R. Kelsey, Barry S. Rosenstein and Lawrence B. Marks

      Version of Record online: 5 DEC 2011 | DOI: 10.1002/cncr.26670

      Although several single-nucleotide polymorphisms have been associated with radiation-induced toxicity in candidate gene studies, there are many important limitations to such analyses. The primary limitations include the approach (candidate gene vs genome wide), small patient numbers, lack of a validation set, and subjective endpoints.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
      Mechanisms of resistance to vascular endothelial growth factor blockade (pages 3455–3467)

      Shaad E. Abdullah and Roman Perez-Soler

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26540

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      New strategies are needed for antiangiogenic cancer therapy to deal with mechanisms of resistance to vascular endothelial growth factor-targeted therapy. Combination approaches currently are under investigation for the treatment of a number of malignancies.

    2. You have free access to this content
      Risk assessment models for cancer-associated venous thromboembolism (pages 3468–3476)

      Mrinal Dutia, Richard H. White and Ted Wun

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26597

      Venous thromboembolism (VTE) is common in cancer patients and is associated with significant morbidity and mortality. In this concise review, the authors discuss risk stratification models that have been specifically developed to identify cancer patients at high risk for VTE and thus might be useful in future studies designed to determine the potential benefit of primary thromboprophylaxis.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Routine clinical use of the one-step nucleic acid amplification assay for detection of sentinel lymph node metastases in breast cancer patients : Results of a multicenter study in Japan (pages 3477–3483)

      Yasuhiro Tamaki, Nobuaki Sato, Keiichi Homma, Daisuke Takabatake, Rieko Nishimura, Masahiko Tsujimoto, Katsuhide Yoshidome, Hitoshi Tsuda, Takayuki Kinoshita, Hironori Kato, Kiyomi Taniyama, Takako Kamio, Seigo Nakamura, Futoshi Akiyama, Shinzaburo Noguchi and and the Japanese One-Step Nucleic Acid Amplification Study Group

      Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.26683

      • original image

      The one-step nucleic acid amplification assay can be used for routine clinical sentinel lymph node biopsy with a 1-mm-thick central slice of the lymph node for pathology. Its assessment for volume of metastasis may be a powerful predictive factor for nonsentinel lymph node metastasis.

    2. Gastrointestinal Disease
      You have free access to this content
      Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma (pages 3484–3493)

      Matias E. Valsecchi, Mary McDonald, Jonathan R. Brody, Terry Hyslop, Boris Freydin, Charles J. Yeo, Charalambos Solomides, Stephen C. Peiper and Agnieszka K. Witkiewicz

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26661

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression in tumoral and stromal cells appears to be an important prognostic factor in patients with pancreatic ductal adenocarcinoma.

    3. You have free access to this content
      Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis (pages 3494–3500)

      Avo Artinyan, Christy L. Marshall, Courtney J. Balentine, Daniel Albo, Sonia T. Orcutt, Samir S. Awad, David H. Berger and Daniel A. Anaya

      Version of Record online: 13 DEC 2011 | DOI: 10.1002/cncr.26682

      • original image

      The authors characterize early postoperative and transitional outcomes in cirrhotic patients undergoing gastrointestinal (GI) cancer surgery. Resection for GI malignancy in patients with cirrhosis is associated with a significantly higher rate of postoperative mortality and discharge to a long-term care facility, with severity of liver disease the primary determinant of both short-term and transitional outcomes.

    4. You have free access to this content
      Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation : Long-term results of a prospective trial (National Clinical Trial 00254683) (pages 3501–3511)

      Rodrigo Oliva Perez, Angelita Habr-Gama, Joaquim Gama-Rodrigues, Igor Proscurshim, Guilherme Pagin São Julião, Patricio Lynn, Carla Rachel Ono, Fabio Guilherme Campos, Afonso Henrique Silva e Sousa Jr., MD, Antonio Rocco Imperiale, Sergio Carlos Nahas and Carlos Alberto Buchpiguel

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26644

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Positron emission tomography/computed tomography imaging may be a useful tool for the assessment of tumor response after neoadjuvant chemoradiotherapy in patients with rectal cancer.

    5. Genitourinary Disease
      You have free access to this content
      Active surveillance for prostate cancer compared with immediate treatment : An economic analysis (pages 3512–3518)

      Kirk A. Keegan, Marc A. Dall'Era, Blythe Durbin-Johnson and Christopher P. Evans

      Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26688

      • original image
      • original image

      Men with prostate cancer represent a source of considerable health care expenditure in the United States. Active surveillance demonstrates considerable cost savings over immediate treatment for a theoretical cohort of men with prostate cancer at 5 years.

    6. Head and Neck Disease
      You have free access to this content
      Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma (pages 3519–3530)

      Parul Sinha, James S. Lewis Jr., Jay F. Piccirillo, Dorina Kallogjeri and Bruce H. Haughey

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26671

      • original image
      • original image
      • original image
      • original image

      Routinely reported extracapsular spread is neither a strong negative prognosticator nor a useful adjuvant therapy determinant in an exclusive cohort of 152 patients with p16-positive oropharyngeal cancer.

    7. Hematologic Malignancies
      You have free access to this content
      The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia (pages 3531–3537)

      Ravin Garg, William Wierda, Alessandra Ferrajoli, Lynne Abruzzo, Sherry Pierce, Susan Lerner, Michael Keating and Susan O'Brien

      Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26593

      • original image
      • original image

      Except for inconsequential differences in albumin and ZAP70 expression, there was no difference in the baseline characteristics between patients with chronic lymphocytic leukemia and monoallelic or biallelic deletion of 13q. In addition, there was no significant difference in endpoints, including time to treatment.

    8. You have free access to this content
      A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas (pages 3538–3548)

      Rajni Sinha, Jonathan L. Kaufman, Hanna Jean Khoury Jr., Nassoma King, Pareen J. Shenoy, Carol Lewis, Kevin Bumpers, Amanda Hutchison-Rzepka, Mourad Tighiouart, Leonard T. Heffner, Mary Jo Lechowicz, Sagar Lonial and Christopher R. Flowers

      Version of Record online: 3 JAN 2012 | DOI: 10.1002/cncr.26660

      • original image
      • original image
      • original image
      • original image

      In this phase 1 dose-escalation study of bortezomib with rituximab plus cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R-CHOP) for patients with untreated follicular lymphoma and other indolent B-cell lymphomas, the results indicate that bortezomib at a maximum tolerated dose of 1.6 mg/m2 in combination with modified R-CHOP does not add to the toxicity of the regimen.

    9. You have free access to this content
      Durable remission with salvage second autotransplants in patients with multiple myeloma (pages 3549–3555)

      Nina Shah, Fraz Ahmed, Qaiser Bashir, Sofia Qureshi, Yvonne Dinh, Gabriela Rondon, Sijin Wen, Peter Thall, Hassan Khan, Sergio Giralt, Richard Champlin and Muzaffar H. Qazilbash

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26662

      • original image
      • original image

      In selected myeloma patients, a second autologous stem cell transplant for salvage therapy is well tolerated, with acceptable toxicity. The response rate and remission duration are comparable to other salvage regimens.

    10. You have free access to this content
      A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias (pages 3556–3564)

      Hanna Jean Khoury, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Maria Cielo Foudray, Martha Arellano, Amelia Langston, Beverly Bethelmie-Bryan, Selena Rush, Kevin Litwiler, Sharon Karan, Heidi Simmons, Adam I. Marcus, Mieke Ptaszynski and Hagop Kantarjian

      Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26664

      • original image
      • original image

      This report discusses a phase 1 trial that identified the maximum tolerated dose and describes the adverse events associated with ARRY-520. The pharmacokinetics of ARRY-520 are reported, as are images of the appearance of abnormal monopolar spindle formation and apoptosis following administration of ARRY-520.

    11. You have free access to this content
      Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD (pages 3565–3570)

      Anthony R. Mato, Jakub Svoboda, Tatyana Feldman, Tania Zielonka, Harry Agress, David Panush, Mitchell Miller, Patrick Toth, Paul M. Lizotte, Sunita Nasta, Stuart Goldberg, Emeline Chong, Steven Schuster, Andrew L. Pecora and Andre Goy

      Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26731

      • original image

      Positron emission tomography (PET)-computed tomography (CT) performed after the completion of dose-intensive immunochemotherapy is an independent predictor of progression-free survival (PFS) with a trend toward predicting overall survival (OS) in mantle cell lymphoma patients. Performing a midtreatment (interim) PET-CT in this patient population does not have prognostic utility for PFS or OS and therefore is not clinically indicated.

    12. Hepatobiliary Disease
      You have free access to this content
      Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era (pages 3571–3578)

      Ryan S. Turley, Peter D. Peng, Srinevas K. Reddy, Andrew S. Barbas, David A. Geller, J. Wallis Marsh, Allan Tsung, Timothy M. Pawlik and Bryan M. Clary

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26650

      In this multicenter retrospective study, the authors observe that overall survival after liver resection and postoperative tyrosine kinase inhibitor (TKI) therapy for the treatment of metastatic gastrointestinal stromal tumor (GIST) exceeds previous reports of liver resection or tyrosine kinase therapy alone. On the basis of the results presented here, the authors recommend that all patients with resectable GIST liver metastases undergo partial hepatectomy and postoperative TKI therapy.

    13. Lung Disease
      You have free access to this content
      Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer (pages 3579–3586)

      June Koo Lee, Heae Surng Park, Dong-Wan Kim, Kimary Kulig, Tae Min Kim, Se-Hoon Lee, Yoon-Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo-Ho Kim and Yung-Jue Bang

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26668

      • original image
      • original image

      Patients who have anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) have a poor prognosis, and their status also is predictive of primary resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors. This finding indicates that conventional treatment options do not produce favorable outcomes for patients with ALK-positive NSCLC.

    14. You have free access to this content
      Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy (pages 3587–3598)

      Xueying Zhao, Xun Wang, Wenting Wu, Zhiqiang Gao, Junjie Wu, David H. Garfield, Haijian Wang, Jiucun Wang, Ji Qian, Huan Li, Li Jin, Qiang Li, Baohui Han, Daru Lu and Chunxue Bai

      Version of Record online: 9 NOV 2011 | DOI: 10.1002/cncr.26669

      • original image

      The authors demonstrate that a genetic variant of matrix metalloproteinase-2, reference polymorphism 12934241 (rs12934241) significantly affects the risk of grade 3 or 4 neutropenia in 663 Chinese patients with advanced nonsmall cell lung cancer receiving first-line, platinum-based regimens. Further stratified analyses reveal that rs12934241 exhibits a much stronger influence on patients receiving cisplatin-gemcitabine regimen than on patients receiving other regimens.

    15. Neuro-Oncology
      You have free access to this content
      Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma (pages 3599–3606)

      Pierre Giglio, Megha Dhamne, Kenneth R. Hess, Mark R. Gilbert, Morris D. Groves, Victor A. Levin, Sanghee L. Kang, Sandra E. Ictech, Vivien Liu, Howard Colman, Charles A. Conrad, Monica Loghin, John de Groot, W. K. Alfred Yung and Vinay K. Puduvalli

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26663

      • original image
      • original image

      In this phase 2 trial that combined the cytotoxic agent irinotecan with the antiangiogenic agent thalidomide, with the hypothesis that this would target 2 critical biological processes of World Health Organization grade III anaplastic gliomas, a subset of patients experienced prolonged progression-free and overall survival; however, the study did not meet its statistical endpoint of progression-free survival at 6 months. A trial of the more potent thalidomide analogue, lenalidomide, with irinotecan is currently ongoing.

    16. You have free access to this content
      A phase 2 study of pegylated interferon α-2b (PEG-Intron®) in children with diffuse intrinsic pontine glioma (pages 3607–3613)

      Katherine Warren, Robyn Bent, Pamela L. Wolters, Alisa Prager, Ryan Hanson, Roger Packer, Joanna Shih and Kevin Camphausen

      Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26659

      • original image

      The authors present results from a phase 2 study of pegylated interferon α-2b in children with diffuse intrinsic pontine glioma. Although no improvement in 2-year survival is observed compared with an historic cohort, there is a potential increase in the time to disease progression, and the agent is well tolerated. The use of biomarkers for futility is discussed.

    17. Discipline

      Clinical Trials
      You have free access to this content
      Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions (pages 3614–3617)

      Peter H. Shaw, Michael Boyiadzis, Hussein Tawbi, Anne Welsh, Aimee Kemerer, Nancy E. Davidson and A. Kim Ritchey

      Version of Record online: 27 DEC 2011 | DOI: 10.1002/cncr.26634

      • original image
      • original image

      Clinical trial enrollment has been associated with outcome. This report demonstrates that clinical trial enrollment in adolescent and young adult (AYA) oncology patients can be improved through the foundation of a collaborative AYA oncology program.

    18. Disparities Research
      You have free access to this content
      Patterns of care and treatment outcomes for elderly women with cervical cancer (pages 3618–3626)

      Charu Sharma, Israel Deutsch, David P. Horowitz, Dawn L. Hershman, Sharyn N. Lewin, Yu-Shiang Lu, Alfred I. Neugut, Thomas J. Herzog, Clifford K. Chao and Jason D. Wright

      Version of Record online: 28 OCT 2011 | DOI: 10.1002/cncr.26589

      • original image

      Elderly women with cervical cancer are less likely to undergo surgery for early stage disease, to receive adjuvant radiation therapy, and to undergo brachytherapy for advanced stage disease. After adjusting for treatment disparities, cancer-specific mortality is higher in older women.

    19. You have free access to this content
      Cancer care challenges in developing countries (pages 3627–3635)

      Adi J. Price, Paul Ndom, Etienne Atenguena, Jean Pierre Mambou Nouemssi and Robert W. Ryder

      Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26681

      • original image
      • original image

      In Cameroon, West Africa, significant barriers to obtaining modern cancer treatment include poor cancer care infrastructure and limited knowledge about cancer among health care providers and patients. The continuing, centuries-old reliance on traditional healers who promise to cure cancers underscores the need for evidence-based cancer awareness programs in Cameroon.

    20. You have free access to this content
      Socioeconomic status and the risk of colorectal cancer : An analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study (pages 3636–3644)

      Chyke A. Doubeni, Adeyinka O. Laiyemo, Jacqueline M. Major, Mario Schootman, Min Lian, Yikyung Park, Barry I. Graubard, Albert R. Hollenbeck and Rashmi Sinha

      Version of Record online: 3 JAN 2012 | DOI: 10.1002/cncr.26677

      • original image

      People with low socioeconomic status have a higher risk for colorectal cancer even after accounting for other risk factors including health behaviors. This association is stronger in the rectum and left colon and relatively weak in the right colon. There are also more right colon cancers for people with high socioeconomic status.

      Corrected by:

      Erratum: Erratum

      Vol. 119, Issue 2, 467–469, Version of Record online: 26 JUN 2012

    21. Quality of Life
      You have free access to this content
      Physical and mental health status of survivors of multiple cancer diagnoses : Findings from the National Health Interview Survey (pages 3645–3653)

      Michael A. Andrykowski

      Version of Record online: 13 DEC 2011 | DOI: 10.1002/cncr.26678

      2009 National Health Interview Survey data are used to compare the physical and mental health status of survivors of multiple primary cancer diagnoses to that of survivors of a single cancer diagnosis and individuals without a history of cancer. Survivors of multiple primary cancer diagnoses report poorer physical and mental health status than survivors of a single cancer diagnosis and individuals without a cancer diagnosis.

    22. Radiation Oncology
      You have free access to this content
      A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy (pages 3654–3665)

      Raymond H. Mak, Brian M. Alexander, Kofi Asomaning, Rebecca S. Heist, Chen-yu Liu, Li Su, Rihong Zhai, Marek Ancukiewicz, Brian Napolitano, Andrzej Niemierko, Henning Willers, Noah C. Choi and David C. Christiani

      Version of Record online: 5 DEC 2011 | DOI: 10.1002/cncr.26667

      • original image

      This is a candidate gene study examining the association between single-nucleotide polymorphisms in oxidative stress genes and radiation pneumonitis in a retrospective cohort of patients treated with thoracic radiation therapy for lung cancer. There was an association between methylene tetrahydrofolate reductase (MTHFR) genotype and risk of clinically significant radiation pneumonitis.

SEARCH

SEARCH BY CITATION